Evidence map›Paper›PMID 42649490›Full record

ArticleBMC pulmonary medicine2026

Rapid recovery from near-fatal immune reconstitution inflammatory syndrome and acute respiratory distress syndrome following neutropenic recovery by cytokine adsorption.

Karl Bihlmaier, Laura Vonbrunn, Axel Schmid, Larissa Herbst, Krystyna Bujok, Felix A Büstgens, Rebecca Wätzig, Heidi Waibel, Mario Schiffer, Carsten Willam

Abstract readCase Reports
In one paragraph

Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Karl BihlmaierDepartment of Internal Medicine 4, Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Ulmenweg 18, 91054, Erlangen, Germany. karl.bihlmaier@uk-erlangen.de.ORCID http://orcid.org/0000-0003-2432-5806
Laura VonbrunnDepartment of Internal Medicine 4, Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Axel SchmidInstitute of Radiology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Maximiliansplatz 3, 91054, Erlangen, Germany.
Larissa HerbstDepartment of Internal Medicine 4, Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Krystyna BujokDepartment of Internal Medicine 4, Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Felix A BüstgensDepartment of Internal Medicine 4, Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Rebecca WätzigDepartment of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Heidi WaibelDepartment of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Mario SchifferDepartment of Internal Medicine 4, Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
Carsten WillamDepartment of Internal Medicine 4, Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the presence of clinical or microbiological evidence of pneumonia, emerging leukocytes in recovery from neutropenia undergo substantial migration to the site of infection, where they elicit immunogenic reactions. The administration of granulocyte colony-stimulating factors is a risk factor for dysregulation of this immune response, which can lead to ARDS. However, there is a paucity of knowledge regarding the severe forms of near-fatal IRIS. CASE PRESENTATION: This case report describes the successful treatment of a hematologic patient with life-threatening Immune Reconstitution Inflammatory Syndrome after recovery from neutropenia and a subsequent acute respiratory distress syndrome involving cytokine adsorption. The present report delineates the case of a 65-year-old male afflicted with plasmoblastic lymphoma and neutropenic sepsis with pneumonia. Escherichia coli was identified in bronchoalveolar lavage fluids, and the patient was successfully treated with piperacillin and tazobactam. After recovering from neutropenia, the patient's respiratory function abruptly worsened, resulting in a secondary, severe ARDS. This deterioration was accompanied by increasing interleukin-6 levels. Therapeutic approaches as prone positioning or volume depletion using renal replacement therapy with high ultrafiltration rates did not lead to a significant respiratory improvement. Initiation of cytokine adsorption resulted in an immediate and absolute respiratory recovery.

conclusionsImmune reconstitution inflammatory syndrome might cause dysregulated pulmonary immune responses following recovery from neutropenia with consecutive severe ARDS. This case report is the first to link IRIS-induced severe ARDS to a hyperinflammatory condition and to the successful therapeutic approach of cytokine adsorption. Ultimately, only cytokine adsorption was able to rapidly improve this suspected IRIS-associated hyperinflammation in an otherwise life-threatening ARDS.

Indexed as

CytokinesImmune Reconstitution Inflammatory SyndromeNeutropeniaRespiratory Distress SyndromeAdsorptionAgedAnti-Bacterial AgentsBronchoalveolar Lavage FluidEscherichia coli InfectionsHumansMalePenicillanic AcidPiperacillinPiperacillin, Tazobactam Drug CombinationSepsisAnti-Bacterial AgentsCytokinesPenicillanic AcidPiperacillinPiperacillin, Tazobactam Drug CombinationAcute respiratory distress syndromeCytokine adsorptionImmune reconstitution inflammatory syndromeNeutropenia

Identifiers

PMID42649490
PMCPMC13508246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.